返回期刊详情

Hepatology International

IF6.1

论文数2108

被引数5858

期刊论文 2108

发表时间

Comparative analysis of ctDNA-MRD and MVI in predicting postoperative recurrence of hepatocellular carcinoma: a prospective multicenter cohort study 比较ctDNA-MRD与MVI在预测肝癌术后复发中的价值：一项前瞻性多中心队列研究

Hepatology International

IF6.1

2026-10-29

OAAI

Yuyan Xu; Cheng Zhang; Wenxuan Liu; Jianan Feng; Chunming Wang; Junming He; Weichao Liang; Qingsong Wu; Yinbing Wu; Weidong Wang; Hongkun Tan; Yaohong Wen; Qing Peng; Jiasheng Zhong; Lei Cai; Mingxin Pan

AI integration for transforming care of patients with liver diseases 人工智能集成用于改善肝病患者护理

Hepatology International

IF6.1

2026-10-29

PREAI

Omkar S. Rudra; Enamundram Naga Karthik; Mamatha Bhat

Higher relapse rate after stopping tenofovir alafenamide compared with entecavir; but not tenofovir disoproxil fumarate in HBeAg-positive patients 与恩替卡韦相比，停药后HBeAg阳性患者替诺福韦艾拉酚胺的复发率更高；但与替诺福韦二吡呋酯无差异

Hepatology International

IF6.1

2026-10-23

PREAI

Kuan-Hung Wan; Cheng-Yuan Peng; Yuan-Hung Kuo; Tsung-Hui Hu; Jing-Houng Wang; Chao-Hung Hung; Sheng-Nan Lu; Chien-Hung Chen

A comprehensive evaluation on the impact of MASLD on the prognosis of chronic hepatitis B-related hepatocellular carcinoma following hepatectomy: results from retrospective multicenter cohort study and meta-analysis 关于MASLD对慢性乙型肝炎相关肝细胞癌肝切除术后预后的影响的综合评价：来自回顾性多中心队列研究和荟萃分析的结果

Hepatology International

IF6.1

2026-10-14

PREAI

Yiyu Chen; Yangyang Ou; Kang Chen; Tianyi Liang; Jiayong Su; Xinping Ye; Liang Ma; Ming Yao; Junjiang Guo; Liang Liang; Jianjun Li; Yuanneng Nong; Ji′an Chen; Fei Huang; Tao Peng; Jian-hong Zhong; Yihe Yan

A real-world multicenter study of statins in compensated advanced chronic liver disease on hepatic decompensation and mortality outcomes 他汀类药物在代偿期晚期慢性肝病中肝功能失代偿和死亡率结局的真实世界多中心研究

Hepatology International

IF6.1

2026-10-14

PREAI

Cheng Han Ng; N. Apoorva Sasikumar; Margaret L. P. Teng; Vincent L. Chen; Jimmy Che-To Lai; Karn Wijarnpreecha; Rahul Kumar; Apichat Kaewdech; Masayuki Ueno; Anand V. Kulkarni; Ming-Hua Zheng; Akash Roy; Ken Liu; Chitchai Rattananukrom; Mazen Noureddin; Mohammad Shadab Siddiqui; Emmanuel Tsochatzis; Mark D. Muthiah; Hirokazu Takahashi

Diverging rate and absolute burden patterns of liver cancer attributable to NASH: global evidence and China as a sentinel case 非酒精性脂肪性肝炎（NASH）所致肝癌的发病率和绝对负担趋势：全球证据与中国作为哨点案例

Hepatology International

IF6.1

2026-10-13

PREAI

Junpeng Luo; Xiao Qi; Yandan Wang

Exploratory analysis of transcriptionally active HBV-host chimeric transcript burden in patients with increasing HBsAg during long-term antiviral therapy 长期抗病毒治疗期间HBsAg升高的患者中转录活跃的HBV-宿主嵌合转录本负担的探索性分析

Hepatology International

IF6.1

2026-10-08

OAAI

Luqi Tang; Bingqiong Wang; Yameng Sun; Shuyan Chen; Guiwen Guan; Jialing Zhou; Tongtong Meng; Wentao Tan; Shuai Xia; Xiaojuan Ou; Jidong Jia; Xiaoning Wu; Hong You

A simple clinical model for predicting multiple liver histologic injuries in obese individuals undergoing bariatric surgery 一种用于预测肥胖接受减肥手术患者多种肝脏组织学损伤的简单临床模型

Hepatology International

IF6.1

2026-10-08

PREAI

Shumin Li; Ziyi Yang; Xin Huang; Mingwei Zhong; Shibo Lin; Teng Liu; Han Zhao; Shaozhuang Liu; Shigang Zhao; Zi-Jiang Chen

Characteristic geoepidemiology and phenotype of autoimmune hepatitis: an 8-year population-based study in Taiwan 自身免疫性肝炎的特征性地理流行病学和表型：一项在台湾进行为期8年的基于人群的研究

Hepatology International

IF6.1

2026-10-08

PREAI

Jur-Shan Cheng; Kai-Feng Sung; Chi-Huan Wu; Chung-Wei Su; Cheng-Jen Chen; Cheng-Yu Lin; Tsung-Hsing Chen; Wei-Ting Chen; Wei-Pin Lin; Yi-Chung Hsieh; Jennifer Tai; Ya-Ting Cheng; Ming-Ling Chang

Plasma proteomic signatures of biological aging and metabolic dysfunction-associated steatotic liver disease risk: a prospective cohort study 生物衰老和代谢功能障碍相关脂肪性肝病风险的血浆蛋白质组学特征：一项前瞻性队列研究

Hepatology International

IF6.1

2026-10-07

PREAI

Teng-Rui Cao; Li-Juan Wu; Xing-Hua Yang; Ning-Fei Fan; Jie Ding; Miao Gong; Xu-Man Feng; Yi-Han Li; Yu-Xiang Yan

Randomised trial of lifestyle interventions for improving metabolic dysfunction-associated steatotic liver disease 随机对照试验：生活方式干预对改善代谢功能障碍相关脂肪性肝病的作用

Hepatology International

IF6.1

2026-10-05

OAAI

Wouter Robaeys; Leen JM. Heyens; Liesbeth Bruckers; Joris Penders; Mathieu Struyve; Ger H. Koek; Sven MA. Francque; Geert KMM. Robaeys

Clinical and pathological significance of serum anti-PD-1 autoantibodies in acute-onset and chronic autoimmune hepatitis 血清抗PD-1自身抗体在急性发作和慢性自身免疫性肝炎中的临床及病理学意义

Hepatology International

IF6.1

2026-09-29

OAAI

Takashi Oda; Akinobu Takaki; Kenichi Harada; Teruko Arinaga-Hino; Masanori Abe; Takeshi Matsui; Atsushi Takahashi; Hiromasa Ohira; Yoshiyuki Suzuki; Nobuhiro Nakamoto; Atsushi Tanaka; Kazuyuki Matsumoto; Jinpeng Li; Nozomi Miyake; Masahiko Sue; Takuya Adachi; Yasuto Takeuchi; Hideki Onishi; Miwa Kawanaka; Motoyuki Otsuka

Circulating fibronectin levels are linked to liver function, matrix remodeling, and hemostatic complications in advanced chronic liver disease 循环纤维连接蛋白水平与晚期慢性肝病中的肝功能、基质重塑和止血并发症相关

Hepatology International

IF6.1

2026-09-25

OAAI

Georg Kramer; Irina Andreea Lie-Ungurean; Benedikt Silvester Hofer; Lukas Hartl; Mathias Jachs; Lorenz Balcar; Georg Semmler; Christian Sebesta; Paul Thöne; Marlene Hintersteininger; Paula Höfinger; Rodrig Marculescu; Thomas Perkmann; Philipp Schwabl; Michael Trauner; Mattias Mandorfer; Thomas Reiberger; Benedikt Simbrunner

The Global ACLF Consensus : the ‘Istanbul Document’全球ACLF共识：伊斯坦布尔文件

Hepatology International

IF6.1

2026-09-24

PREAI

Anand V. Kulkarni; Ashok Choudhury; Vinod Arora; Abdul Kadir Dokmeci; Abraham Koshy; Ahmet Gurakar; Ajay Duseja; Akash Roy; Akash Shukla; Aleksander Krag; Alfred Wei Chieh Kow; Ananta Shrestha; Apichat Kaewdech; Ashish Goel; Ashish Kumar; Ashwani K. Singal; Aung Hlaing Bwa; Chanunta Hongthanakorn; Cosmas Rinaldi Adithya Lesmana; Daniel Huang; Darrell Crawford; Debbie Shawcross; Deniz Balchi; Dhiraj Agrawal; Diana A. Payawal; Do Seon Song; Dong Joon Kim; Fernando Bessone; George K. Lau; Giacomo Germani; Girish Kumar Pati; Grace L. Su; Guan-Huei Lee; Gupse Adali; Gyongyi Szabo; Hasmik Ghazinian; Jacob George; James Fung; Jasmohan Bajaj; P. Javed; Jidong Jia; Jimmy Che-To Lai; Jin Jun Chen; Jonel Trebicka; Jun Li; Kavish Patidar; Kemal Fariz Kalista; Ken Liu; Kessarin Thanapirom; Lai Wei; M. Golam Azam; Madhumita Premkumar; Madunil Niriella; Manasa Alla; Mangesh Pagadala; Manoj Kumar; Manuel Mendizabal; Mario Guimaraes Pessoa; Mark Dhinesh Muthiah; Masao Omata; Mazen Noureddin; Md. Fazal Karim; Mithun Sharma; Mohamed Alboraie; Mohamed Elbasiony; Murat Harputluoglu; Narendra Singh Choudhary; Nazia Selzner; Necati Ormeci; Nelia Hernandez; Nipun Verma; Paolo Angeli; Phunchai Charatcharoenwitthaya; Prabir Maji; Pravin Rathi; R. K. Dhiman; Rahul Kumar; Rakhi Maiwall; Ramazan Idilman; Richard Moreau; Rino A. Gani; Rosmawati Mohamed; S. S. Hamid; Sanjeev Sachdeva; Senamjit Kaur; Shahinul Alam; Soe Thiha Maung; Soek-Siam Tan; T. R. Sowmya; K. C. Sudhamshu; Sumana Ramachandra; Sunil Kumar Dadhich; Sunil Taneja; Suprabhat Giri; Surender Singh; Tao Chen; Tarana Gupta; Tushar Madke; V. M. Dayal; Venishetty Shantan; Viniyendra Pamecha; Wong Yu Jun; Xiaolong Qi; Yoon Jun Kim; Zaigham Abbas; Zobair M. Younossi; Shiv Kumar Sarin

Dynamic changes in controlled attenuation parameter (CAP) improve prognostic prediction for CHB patients with significant fibrosis and cirrhosis 控制性衰减参数（CAP）的动态变化提高了具有显著纤维化和肝硬化的慢性乙型肝炎（CHB）患者的预后预测

Hepatology International

IF6.1

2026-09-19

PREAI

Xiaowei Ai; Mengyang Zhang; Shuyan Chen; Xinyu Zhao; Jialing Zhou; Tongtong Meng; Bingqiong Wang; Chenglin Sun; Xiao Han; Yankun Gao; Xiaoning Wu; Hong You; Yameng Sun

How to apply artificial intelligence (AI) to facilitate and enhance MASH trials 如何应用人工智能(AI)促进和提高MASH试验

Hepatology International

IF6.1

2026-09-16

PREAI

Daniel Yan Zheng Lim; Wei Qiang Leow; Daniela S. Allende; Wai Kay Seto; Terry Cheuk-Fung Yip; George Boon Bee Goh

Coronary atherosclerosis across stages of metabolic dysfunction–associated steatotic liver disease: a VCTE–CCTA study 代谢功能障碍相关脂肪性肝病各阶段冠状动脉动脉粥样硬化：一项VCTE–CCTA研究

Hepatology International

IF6.1

2026-09-16

OAAI

Gediz Dogay Us; Francesco Innocenti; Ozgur Muhammet Koc; Sevval İlke Ebeoglu; Baris Okcun; İhsan Nuri Akpinar; Melih Hulusi Us; Ger H. Koek

Noninvasive surrogate endpoints in MASH trials: current perspectives and challenges 非侵入性替代终点在MASH试验中的现状与挑战

Hepatology International

IF6.1

2026-09-13

OAAI

Hye Won Lee; Luis Antonio Díaz; Vincent Wai-Sun Wong; Wah Kheong Chan

Antiviral therapies are associated with reduced mortality but under-utilized in patients with viral hepatocellular carcinoma: a multinational REAL-HCC study 抗病毒疗法与降低病毒性肝细胞癌患者死亡率相关，但使用率较低：一项跨国REAL-HCC研究

Hepatology International

IF6.1

2026-09-11

PREAI

Taotao Yan; Pei-Chien Tsai; Ming-Lun Yeh; Dae Won Jun; Hidenori Toyoda; Yao-Chun Hsu; Jennifer Leong; Xiaozhong Wang; Xu Qiang; Hiroshi Abe; Takanori Suzuki; Chia-Yen Dai; Jee-Fu Huang; Wan-Long Chuang; Chung-Feng Huang; Yao-Li Chen; Ping-Yi Lin; Satoshi Yasuda; Joanne Kimiko Liu; Mayumi Maeda; Eiichi Ogawa; Cheng-Hao Tseng; Maria Buti; Philip Vutien; Yu Jun Wong; Huy Trinh; Takashi Honda; Haruki Uojima; Masaru Enomoto; Yasuhito Tanaka; Myron Schwartz; Ramsey Cheung; Ming-Lung Yu; Mindie H. Nguyen

Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea 仑伐替尼与索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌患者的二线治疗真实世界疗效：一项韩国大规模多中心研究

Hepatology International

IF6.1

2026-09-11

OAAI

Min Ji Lee; Subin Lim; Jae Yong Shim; Mi Na Kim; DongKyu Kim; Kyu‑pyo Kim; Kang Mo Kim; Baek‑Yeol Ryoo; Won‑Mook Choi; Hyun‑Jeong Kim; Seung‑Hoon Lee; Gaeun Kang; Mira Kang; Won Chul Cha; Jung Yong Hong; Woo Kyoung Jeong; Sung Kyung Ju; Jung‑Hyun Won; Doik Lee; Jiyoon Ahn; Do Young Kim